Abstract | BACKGROUND: MATERIALS AND METHODS: Patients undergoing resection for CRC (n = 175) were recruited from July 2003 to December 2004. MMP-7 was determined using a quantitative solid phase sandwich ELISA. Cox analysis was used to assess the role of MMP-7 in predicting overall survival (OS) and disease-free survival (DFS). RESULTS: The median length of follow-up was 45 months (range 1 to 59). Levels of MMP-7 are predictors of DFS (hazard ratio [HR] 1.119, 95% confidence interval [95% CI] 1.038-1.207) and of OS (HR 1.113, 95% CI 1.025-1.209). Patients with MMP-7 higher than the median (4.3 ng/ml) are more likely to relapse (29.5% vs 18.4%, P = .084); median time to progression in relapsed patients is 8 months if MMP-7 is > or =4.3 ng/ml and 18 months if MMP-7 is <4.3 ng/ml. Node-negative patients with low MMP-7 have a predicted probability of relapse-free survival at 4 years of 88% (95% CI 83-92%); if the MMP-7 is higher than the median value; this probability is 77% (95% CI 73-81%). CONCLUSION: MMP-7 predicts recurrence in curatively resected CRC patients.
|
Authors | Alejandro Martínez-Fernandez, Xabier García-Albeniz, Estela Pineda, Laura Visa, Rosa Gallego, Jordi Codony-Servat, Josep Maria Augé, Raquel Longarón, Pere Gascón, Antonio Lacy, Antoni Castells, Joan Maurel |
Journal | Annals of surgical oncology
(Ann Surg Oncol)
Vol. 16
Issue 5
Pg. 1412-20
(May 2009)
ISSN: 1534-4681 [Electronic] United States |
PMID | 19259740
(Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Biomarkers, Tumor
- Matrix Metalloproteinase 7
|
Topics |
- Adenocarcinoma
(blood, mortality, therapy)
- Adult
- Aged
- Aged, 80 and over
- Biomarkers, Tumor
(blood)
- Colectomy
- Colorectal Neoplasms
(blood, mortality, therapy)
- Combined Modality Therapy
- Female
- Humans
- Male
- Matrix Metalloproteinase 7
(blood)
- Middle Aged
- Predictive Value of Tests
- Prognosis
- Prospective Studies
- Survival Analysis
|